New shot aims to stop bleeds in rare blood disorder
NCT ID NCT06998524
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants aged 1 month and older will receive regular injections of emicizumab or continue their current standard care. The main goal is to see if emicizumab reduces the number of bleeds that need treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE, TYPE 3 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Careggi
RECRUITINGFlorence, Tuscany, 50134, Italy
-
Charlotte Maxeke Johannesburg Academic Hospital
RECRUITINGJohannesburg, 2193, South Africa
-
Erasmus MC
RECRUITINGRotterdam, 3015 GD, Netherlands
-
Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz
RECRUITINGDuisburg, 47051, Germany
-
Great Ormond Street Hospital
RECRUITINGLondon, WC1N 3JH, United Kingdom
-
Groupe Hospitalier Necker Enfants Malades
RECRUITINGParis, 75015, France
-
Hopital Claude Huriez - CHU Lille
RECRUITINGLille, 59037, France
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, 41013, Spain
-
Hospital Universitario la Paz
RECRUITINGMadrid, 28046, Spain
-
Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin
RECRUITINGFrankfurt/M., 60590, Germany
-
IPS SURA Industriales Medellín
RECRUITINGMedellín, Colombia
-
IRCCS Ca' Granda Ospedale Maggiore Policlinico
RECRUITINGMilan, Lombardy, 20122, Italy
-
Instytut Hematologii i Transfuzjologii
RECRUITINGWarsaw, 02-776, Poland
-
Kurume University Hospital
RECRUITINGFukuoka, 830-0011, Japan
-
Manchester Royal Infirmary
RECRUITINGManchester, M13 9WL, United Kingdom
-
McGill University Health Center
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Nagoya University Hospital
RECRUITINGNagoya, 466-8560, Japan
-
Sahlgrenska Universitetssjukhuset
RECRUITINGGothenburg, S-413 45, Sweden
-
St Thomas' Hospital
RECRUITINGLondon, SE1 7EH, United Kingdom
-
The Hospital for Sick Children
RECRUITINGToronto, Ontario, M5G 1X8, Canada
-
UC Davis
RECRUITINGSacramento, California, 95817, United States
-
UZ Leuven Gasthuisberg
RECRUITINGLeuven, 3000, Belgium
-
Universita' Degli Studi La Sapienza-Ist.Di Ematologia
RECRUITINGRome, Lazio, 00161, Italy
-
University of Florida
RECRUITINGGainesville, Florida, 32610, United States
-
University of Minnesota Medical Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Universitätsklinikum Bonn
RECRUITINGBonn, 53127, Germany
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.